Stoke Therapeutics Inc STOK.OQ STOK.O is expected to show a rise in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
The Bedford Massachusetts-based company is expected to report a 80.6% increase in revenue to $7.614 million from $4.22 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Stoke Therapeutics Inc is for a loss of 43 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 2.0% in the last three months.
Wall Street's median 12-month price target for Stoke Therapeutics Inc is $21.00, above its last closing price of $9.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.52 | -0.53 | -0.18 | Beat | 65.9 |
Sep. 30 2024 | -0.53 | -0.53 | -0.47 | Beat | 11.8 |
Jun. 30 2024 | -0.56 | -0.56 | -0.46 | Beat | 17.9 |
Mar. 31 2024 | -0.61 | -0.61 | -0.57 | Beat | 6.6 |
Dec. 31 2023 | -0.48 | -0.63 | -0.60 | Beat | 4.8 |
Sep. 30 2023 | -0.64 | -0.63 | -0.55 | Beat | 12.4 |
Jun. 30 2023 | -0.62 | -0.64 | -0.69 | Missed | -8.4 |
Mar. 31 2023 | -0.68 | -0.70 | -0.53 | Beat | 23.9 |
This summary was machine generated May 2 at 14:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)